These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29038235)

  • 61. Hard Palate Melanoma: A Population-based Analysis of Epidemiology and Survival Outcomes.
    Oranges CM; Sisti G; Nasioudis D; Tremp M; DI Summa PG; Kalbermatten DF; Largo RD; Schaefer DJ
    Anticancer Res; 2018 Oct; 38(10):5811-5817. PubMed ID: 30275204
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.
    Inoue K; Ninomiya J; Saito T; Okubo K; Nakakuma T; Yamada H; Kimizuka K; Higuchi T;
    Invest New Drugs; 2019 Jun; 37(3):538-547. PubMed ID: 30848403
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center.
    Parker BA; Schwaederlé M; Scur MD; Boles SG; Helsten T; Subramanian R; Schwab RB; Kurzrock R
    J Oncol Pract; 2015 Nov; 11(6):442-9. PubMed ID: 26243651
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine.
    Bashraheel SS; Domling A; Goda SK
    Biomed Pharmacother; 2020 May; 125():110009. PubMed ID: 32106381
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
    Shi H; Zhang W; Bi X; Wang D; Xiao Z; Guan Y; Guan K; Tian J; Bai H; Hu L; Cao C; Jiang W; Hu Z; Zhang J; Chen Y; Zheng S; Feng X; Li C; Li Y; Ma J; Liu Y; Zhou A; Shou J
    Cancer Res Treat; 2021 Oct; 53(4):1156-1165. PubMed ID: 33592141
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
    Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
    Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
    Fang H; Lin RY; Sun MX; Wang Q; Zhao YL; Yu JL; Tian Y; Wang XY
    Asian Pac J Cancer Prev; 2014; 15(24):10967-70. PubMed ID: 25605210
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival.
    Baumgartner JM; Raymond VM; Lanman RB; Tran L; Kelly KJ; Lowy AM; Kurzrock R
    Ann Surg Oncol; 2018 Aug; 25(8):2400-2408. PubMed ID: 29948422
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
    Nieto Y; Tu SM; Bassett R; Jones RB; Gulbis AM; Tannir N; Kingham A; Ledesma C; Margolin K; Holmberg L; Champlin R; Pagliaro L
    Ann Oncol; 2015 Oct; 26(10):2125-32. PubMed ID: 26199392
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Prognostic and Therapeutic Value of the Mutational Profile of Blood and Tumor Tissue in Head and Neck Squamous Cell Carcinoma.
    Wilson HL; D'Agostino RB; Meegalla N; Petro R; Commander S; Topaloglu U; Zhang W; Porosnicu M
    Oncologist; 2021 Feb; 26(2):e279-e289. PubMed ID: 33098199
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
    Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.
    Rodriguez-Freixinos V; Lheureux S; Mandilaras V; Clarke B; Dhani NC; Mackay H; Butler MO; Wang L; Siu LL; Kamel-Reid S; Stockley T; Bedard PL; Oza AM
    Gynecol Oncol; 2019 May; 153(2):304-311. PubMed ID: 30792002
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Transarterial chemoperfusion of the pelvis--results in symptomatic locally recurrent tumors and lymph node metastases].
    Vogl TJ; Zangos S; Eichler K; Balzer JO; Jacob U; Keilhauer R; Bauer RW
    Rofo; 2007 Nov; 179(11):1174-80. PubMed ID: 17805998
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix.
    Eralp Y; Saip P; Sakar B; Kucucuk S; Aydiner A; Dincer M; Aslay I; Topuz E
    Int J Gynecol Cancer; 2003; 13(4):497-504. PubMed ID: 12911727
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
    Kim JJ; Ryu MH; Yoo C; Beck MY; Ma JE; Kang YK
    Oncologist; 2019 Nov; 24(11):e1212-e1218. PubMed ID: 31036770
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study.
    Beltrame L; Di Marino M; Fruscio R; Calura E; Chapman B; Clivio L; Sina F; Mele C; Iatropoulos P; Grassi T; Fotia V; Romualdi C; Martini P; Noris M; Paracchini L; Craparotta I; Petrillo M; Milani R; Perego P; Ravaggi A; Zambelli A; Ronchetti E; D'Incalci M; Marchini S
    Ann Oncol; 2015 Jul; 26(7):1363-71. PubMed ID: 25846551
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Impact of external-beam radiation therapy on outcomes among patients with resected gastric cancer: a multi-institutional analysis.
    Ejaz A; Spolverato G; Kim Y; Squires MH; Poultsides G; Fields R; Bloomston M; Weber SM; Votanopoulos K; Worhunsky DJ; Swords D; Jin LX; Schmidt C; Acher AW; Saunders N; Cho CS; Herman JM; Maithel SK; Pawlik TM
    Ann Surg Oncol; 2014 Oct; 21(11):3412-21. PubMed ID: 24845728
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience.
    De Pasquale MD; D'Angelo P; Crocoli A; Boldrini R; Conte M; Bisogno G; Spreafico F; Inserra A; Biasoni D; Dall'Igna P; Siracusa F; Miele E; Terenziani M
    Pediatr Blood Cancer; 2020 Mar; 67(3):e28125. PubMed ID: 31850649
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Bi-allelic Mutations in TTC29 Cause Male Subfertility with Asthenoteratospermia in Humans and Mice.
    Liu C; He X; Liu W; Yang S; Wang L; Li W; Wu H; Tang S; Ni X; Wang J; Gao Y; Tian S; Zhang L; Cong J; Zhang Z; Tan Q; Zhang J; Li H; Zhong Y; Lv M; Li J; Jin L; Cao Y; Zhang F
    Am J Hum Genet; 2019 Dec; 105(6):1168-1181. PubMed ID: 31735294
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Exploring heterogeneity of adrenal cortical tumors in children: The French pediatric rare tumor group (Fracture) experience.
    Picard C; Faure-Conter C; Leblond P; Brugières L; Thomas-Teinturier C; Hameury F; Defachelles AS; Verschuur A; Brisse HJ; Sarnacki S; Dijoud F; Reguerre Y; Chastagner P; Carton M; Orbach D
    Pediatr Blood Cancer; 2020 Feb; 67(2):e28086. PubMed ID: 31738008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.